FLT3 and acute myeloid leukemia: Additionally, 2-DG alone demonstrated strong antileukemic effects in both AML cell lines and primary samples harboring FLT3-ITD and KIT mutations also through inhibition of N-glycosylation and surface expression of the mutant receptor tyrosine kinases (40).